



Quantum-Si to Present at the B. Riley Securities' Disruptive Biotech Enabling Technologies Virtual Mini Conference

March 28, 2022

GUILFORD, Conn.--(BUSINESS WIRE)-- Mar. 28, 2022--[Quantum-Si Incorporated](#) (Nasdaq: QSI) ("Quantum-Si," "QSI" or the "Company"), a life sciences company commercializing single molecule protein sequencing, today announced that it will be participating in the B. Riley Disruptive Biotech Enabling Technologies Virtual Mini Conference.

Quantum-Si's management is scheduled to present virtually on Thursday, April 7, 2022 at 10:20 am ET. To listen to the live event, please contact your B. Riley Securities representative with interest.

About Quantum-Si Incorporated

Quantum-Si is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single molecule next-generation protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at www.quantum-si.com.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20220328005817/en/): <https://www.businesswire.com/news/home/20220328005817/en/>

Investor Contacts

Juan Avendano
Mike Cavanaugh
ir@quantum-si.com

Media

Jon Yu
QSI-PR@westwicke.com

Source: Quantum-Si Incorporated